Cargando…

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Maggi, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917143/ https://www.ncbi.nlm.nih.gov/pubmed/36768811 http://dx.doi.org/10.3390/ijms24032488

Ejemplares similares

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules
por: Focosi, Daniele, et al.
Publicado: (2023)

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Recombination in Coronaviruses, with a Focus on SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
por: Focosi, Daniele, et al.
Publicado: (2023)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

SARS-CoV-2 recombinant XN, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody
por: Moscato, Giovanna, et al.
Publicado: (2021)

An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
por: Miller, Nathaniel L., et al.
Publicado: (2021)

Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID-19 Serology in Oncology Staff Study: Understanding SARS-CoV-2 in the Oncology Workforce
por: Favara, D.M., et al.
Publicado: (2021)

TTV viral load as a predictor of antibody response to SARS COV-2 vaccination
por: Focosi, Daniele, et al.
Publicado: (2023)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

Serology Testing for SARS-CoV-2: Benefits and Challenges
por: Jalali Nadoushan, Mohammadreza, et al.
Publicado: (2020)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

The value of serology testing to manage SARS-CoV-2 infections
por: Fernández-Barat, Laia, et al.
Publicado: (2020)

Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers.
por: Focosi, Daniele, et al.
Publicado: (2023)

Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants
por: Lopez-Morales, Joanan, et al.
Publicado: (2023)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?
por: Focosi, Daniele, et al.
Publicado: (2022)

Serological Tests in the Detection of SARS-CoV-2 Antibodies
por: Guevara-Hoyer, Kissy, et al.
Publicado: (2021)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Searching for escape-resistant anti–SARS-CoV-2 neutralizing antibodies
por: Mahla, Ranjeet Singh, et al.
Publicado: (2022)

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
por: Cao, Yunlong, et al.
Publicado: (2021)

Multi-task learning for predicting SARS-CoV-2 antibody escape
por: Gross, Barak, et al.
Publicado: (2022)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
por: Ragonnet-Cronin, Manon, et al.
Publicado: (2023)

Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies
por: James, Joe, et al.
Publicado: (2021)

Longitudinal detection of SARS‐CoV‐2‐specific antibody responses with different serological methods
por: Emmerich, Petra, et al.
Publicado: (2021)

Sensitive detection of anti‐spike antibodies enables improved understanding of SARS‐CoV‐2 pathogenesis
por: Milling, Simon
Publicado: (2021)

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
por: Lou, Fuxing, et al.
Publicado: (2021)

Serological testing for SARS-CoV-2: Advancements and future challenges
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c1hnbf5u3sj55rgqlrdsgdirkc